Taurus Vaccines Inc.
Biotechnology company (founded 2024, Austin, TX) focused on early-stage development of next-generation vaccines for livestock. Uses a double-attenuated influenza virus vector platform to elicit cytotoxic T-lymphocyte and humoral responses. Provides R&D and pre-licensing development services, in silico epitope design, support for field trials, and regulatory registration assistance, with an emphasis on scalable production compatible with existing influenza vaccine infrastructure.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Equine influenza vaccine candidate
Early-stage vaccine candidate targeting equine influenza designed using the attenuated influenza virus vector platform.
Johne's disease vaccine candidate
Vaccine candidate aimed at Mycobacterium avium subspecies paratuberculosis for prevention of Johne's Disease in ruminants.
Brucellosis vaccine candidate
Vaccine candidate targeting Brucella spp. to prevent brucellosis-related reproductive loss and productivity decline in livestock.
Bovine leukemia virus (BLV) vaccine candidate
Vaccine candidate addressing Bovine Leukemia Virus to reduce enzootic bovine leukosis and associated economic losses in dairy and beef herds.
Equine influenza vaccine candidate
Early-stage vaccine candidate targeting equine influenza designed using the attenuated influenza virus vector platform.
Johne's disease vaccine candidate
Vaccine candidate aimed at Mycobacterium avium subspecies paratuberculosis for prevention of Johne's Disease in ruminants.
Brucellosis vaccine candidate
Vaccine candidate targeting Brucella spp. to prevent brucellosis-related reproductive loss and productivity decline in livestock.
Bovine leukemia virus (BLV) vaccine candidate
Vaccine candidate addressing Bovine Leukemia Virus to reduce enzootic bovine leukosis and associated economic losses in dairy and beef herds.
Services
Design and development of tailored vaccine candidates for livestock based on a double-attenuated influenza virus vector platform.
Rapid computational analysis of pathogen protein sequences to select MHCI-binding CTL epitopes and design optimized vaccine inserts.
Scale-up process development for egg-based and Vero cell–based vaccine production, including high-titer propagation methods.
Development of purification workflows based on tangential flow filtration and diafiltration, with formulation stability and lyophilization optimization.
Operational support for field trials and assistance with regulatory submission and registration pathways for veterinary vaccines.
Characterization and preparation of vaccine candidates for out-licensing to commercial manufacturers and distributors.
Design and development of tailored vaccine candidates for livestock based on a double-attenuated influenza virus vector platform.
Rapid computational analysis of pathogen protein sequences to select MHCI-binding CTL epitopes and design optimized vaccine inserts.
Scale-up process development for egg-based and Vero cell–based vaccine production, including high-titer propagation methods.
Development of purification workflows based on tangential flow filtration and diafiltration, with formulation stability and lyophilization optimization.
Operational support for field trials and assistance with regulatory submission and registration pathways for veterinary vaccines.
Characterization and preparation of vaccine candidates for out-licensing to commercial manufacturers and distributors.
Expertise Areas
- Vaccine platform development
- Livestock vaccine R&D
- Immunoinformatics and epitope design
- Viral vector engineering
Key Technologies
- Attenuated influenza virus vector design
- Immunoinformatics / epitope mapping
- Embryonated egg-based vaccine production
- Vero cell-based production (serum-free adaptation)
News & Updates
Taurus Vaccines LLC founded and headquartered in Austin, Texas (company established 2024).
Phase 1 clinical trial for the vector-based influenza candidate demonstrated a replication-deficient phenotype and favorable safety profile after intranasal administration.
Taurus Vaccines LLC founded and headquartered in Austin, Texas (company established 2024).
Phase 1 clinical trial for the vector-based influenza candidate demonstrated a replication-deficient phenotype and favorable safety profile after intranasal administration.